MiR-320a upregulation contributes to the effectiveness of pemetrexed by inhibiting the growth and invasion of human lung cancer cell line (Calu-6)

• Published in: Molecular biology reports 2024-12, Vol.51 (1), p.310-310, Article 310
• Main Authors: Ghorbani Alvanegh, Akbar, Arpanaei, Ayyoob, Esmaeili Gouvarchin Ghaleh, Hadi, Mohammad Ganji, Shahla
• Format: Article
• Language: English
• Subjects: Animal Anatomy; Animal Biochemistry; Apoptosis; BAX protein; Bcl-2 protein; bcl-2-Associated X Protein - genetics; Biomedical and Life Sciences; Cancer therapies; Carbon dioxide; Caspase-3; Cell growth; Cell Line; cell lines; Chemotherapy; Chromosome 3; Dihydrofolate reductase; drug therapy; Environmental stress; Enzymatic activity; enzyme activity; Gene expression; growth retardation; Histology; Humans; humidity; L-Lactate dehydrogenase; lactate dehydrogenase; Life Sciences; Lung cancer; lung neoplasms; Lung Neoplasms - drug therapy; Lung Neoplasms - genetics; microRNA; MicroRNAs - genetics; miRNA; Morphology; neoplasm cells; Original Article; Pemetrexed - pharmacology; Stat3 protein; Up-Regulation - genetics
• ISSN: 0301-4851; 1573-4978
• DOI: 10.1007/s11033-024-09207-z

Background Lung cancer is a common and deadly disease. Chemotherapy is the most common treatment, which inhibits cancer cell growth. Pemetrexed (PMX) is often used with other drugs. Environmental stress can affect regulatory non-coding RNAs such as MicroRNAs that modify gene expression. This study investigates the effect of PMX on the hsa-miR-320a-3p expression in the Calu-6 lung cancer cell line. Methods and result Calu-6 cells were cultured in an incubator with 37 °C, 5% CO2, and 98% humidity. The MTT test was performed to determine the concentration of PMX required to inhibit 50% of cell growth. To examine growth inhibition and apoptosis, release of lactate dehydrogenase (LDH), cell assays and caspase 3 and 7 enzyme activity were used. Finally, molecular studies were conducted to compare the expression of hsa-miR-320a-3p and genes including VDAC1, DHFR, STAT3, BAX and BCL2 before and after therapy. Results According to a study, it has been observed that PMX therapy significantly increases LDH release after 24 h. The study found that PMX's IC 50 on Calu-6 is 8.870 µM. In addition, the treated sample showed higher expression of hsa-miR-320a-3p and BAX , while the expression of VDAC1, STAT3, DHFR and BCL2 decreased compared to the control sample. Conclusion According to the findings of the current research, hsa-miR-320a-3p seems to have the potential to play an important role in the development of novel approaches to the treatment of lung cancer.